<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE339nnn/GSE339077/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE339077</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Fibronectin inhibition restores myelination in endothelial TNFR2-depedent non-remitting Experimental Autoimmune Encephalomyelitis [RNA-seq]</name><description>Multiple Sclerosis (MS) is characterized by impaired remyelination and progressive neurodegeneration. Here, we investigated the mechanisms underlying remyelination failure in Experimental Autoimmune Encephalomyelitis (EAE), a murine model of MS. Tumor Necrosis Factor Receptor 2 (TNFR2) deletion causes a severe non-remitting disease after EAE induction. To delineate the TNFR2-dependent effect on remyelination, we assessed the transcriptional profiles of mice expressing TNFR2 (TNFR2FF) and TNFR2-deleted mice (TNFR2KO) at key EAE stages. Our study highlights the key role of TNFR2 at the non-remitting stage of the disease.</description><dates><publication>2026/09/07</publication></dates><accession>GSE339077</accession><cross_references><GSM>GSM9888093</GSM><GSM>GSM9888094</GSM><GSM>GSM9888091</GSM><GSM>GSM9888092</GSM><GSM>GSM9888097</GSM><GSM>GSM9888086</GSM><GSM>GSM9888087</GSM><GSM>GSM9888098</GSM><GSM>GSM9888095</GSM><GSM>GSM9888096</GSM><GSM>GSM9888085</GSM><GSM>GSM9888090</GSM><GSM>GSM9888099</GSM><GSM>GSM9888088</GSM><GSM>GSM9888100</GSM><GSM>GSM9888089</GSM><GPL>16331</GPL><GSE>339077</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>